FibroGen’s Roxadustat Faces US FDA Scrutiny On ‘Prominent’ Safety Signals Relative To Erythropoietin

 
• By Sue Sutter
  
Muddy tracks
Safety concerns have muddied the FDA's view of roxadustat's benefits in chronic kidney disease. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers